Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| no clinical added value |
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO). |
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
mUf9NTb8qg9twVmj
